Janice Jean Murray Buys 1,900 Shares of Knight Therapeutics Inc. (TSE:GUD) Stock

Knight Therapeutics Inc. (TSE:GUDGet Rating) Director Janice Jean Murray purchased 1,900 shares of the firm’s stock in a transaction dated Wednesday, April 13th. The stock was bought at an average cost of C$5.30 per share, for a total transaction of C$10,070.00. Following the acquisition, the director now directly owns 6,115 shares in the company, valued at C$32,409.50.

GUD traded up C$0.02 during trading on Friday, hitting C$5.35. 89,300 shares of the stock traded hands, compared to its average volume of 250,789. The firm has a market capitalization of C$626.09 million and a P/E ratio of 42.46. The company has a debt-to-equity ratio of 4.86, a current ratio of 2.90 and a quick ratio of 2.09. The firm has a 50-day moving average of C$5.41 and a 200 day moving average of C$5.35. Knight Therapeutics Inc. has a 12-month low of C$5.01 and a 12-month high of C$5.74.

Knight Therapeutics (TSE:GUDGet Rating) last posted its earnings results on Thursday, March 24th. The company reported C($0.08) EPS for the quarter. The firm had revenue of C$58.27 million for the quarter, compared to analysts’ expectations of C$61.00 million. As a group, equities analysts predict that Knight Therapeutics Inc. will post 0.06 EPS for the current fiscal year.

GUD has been the topic of several recent research reports. Raymond James set a C$7.50 target price on shares of Knight Therapeutics and gave the company an “outperform” rating in a report on Friday, April 1st. National Bankshares reduced their target price on shares of Knight Therapeutics from C$8.00 to C$7.50 and set an “outperform” rating on the stock in a report on Friday, March 25th. National Bank Financial reduced their target price on shares of Knight Therapeutics from C$8.00 to C$7.50 and set an “outperform” rating on the stock in a report on Friday, March 25th. Bloom Burton reaffirmed a “buy” rating and set a C$6.70 target price on shares of Knight Therapeutics in a report on Monday, March 28th. Finally, Canaccord Genuity Group dropped their price target on shares of Knight Therapeutics from C$8.00 to C$7.00 in a research report on Friday, March 25th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of C$7.00.

About Knight Therapeutics (Get Rating)

Knight Therapeutics Inc, a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma.

Read More

Insider Buying and Selling by Quarter for Knight Therapeutics (TSE:GUD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.